Torrent Pharmaceuticals Ltd.
Snapshot View

View in App

Prices View details

3079.20 +36.00 ▲1.2%

26 July 2021, 04:02:11 P.M.
Volume: 263,353

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.torrentpharma.com
Financial Indicators
Market Cap 52,102.75 Cr.
Earnings per share (EPS) 73.98 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 41.62 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 344.97 Trailing Twelve Months Ending 2021-03
Price to Book Value 8.93 Calculated using Price: 3,079.20
Dividend Yield 1.14 Period Ending 2021-03
No. of Shares Subscribed 16.92 Cr. 169,208,720 Shares
FaceValue 5
Company Profile

Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.

Business area of the company

Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.

Manufacturing facilities

The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum.

Awards and recognition

  • 1984-85 Received Chemexcil Export Award
  • 1984-85 Received Udyog Ratna Award
  • 1985-86 Received Chemexcil Export Award
  • 1986-87 Received Chemexcil Export Award
  • 1986-87 Received IDMA Quality Excellence Award
  • 1986-87 Received Export Award from Govt. of Gujarat
  • 1987-88 Received Export Award from Govt. of Gujarat
  • 1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
  • 1989-90 Received IDMA Quality Excellence Award
  • 1988-89 Received Chemexcil Export Award
  • 1990-91 Received Export Award from Govt. of Gujarat
  • 1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
  • 1991-92 Received Export Award from Govt. of Gujarat
  • 1991-92 Received National Export Award
  • 1992-93 Received IDMA Quality Excellence Award
  • 1999-00 GCCI Export Appreciation Award
  • 1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
  • 2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
  • 2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
  • 2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2009-10 Baddi Plant awarded Five Star rating by British Safety Council
  • 2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category

Accreditation

Approvals research centre

  • National GLP Compliance Monitoring Authority, India*
  • National Accreditation Board for Testing & Calibration Laboratories (NABL), India*
  • ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*
  • ISO 50001 : 2011, ISOQAR Ltd. UK*

(*Also applicable for Bio-Evaluation Center)

Bio-evaluation centre accreditations

  • The Drug Controller General (India) (DCGI)
  • ANVISA (BRAZIL)
  • Ministry of Health (UAE)

Studies inspected and approved

  • USFDA
  • AFFSAPS (ANSM)
  • DKMA
  • AGES
  • ANVISA

Studies accepted by Regulatory Agencies in:

  • Russia
  • CIS Countries
  • Australia
  • ASEAN countries
  • South Africa
  • African countries
  • South American countries

Milestones

  • 1959: U. N. Mehta started Pharma operations.
  • 1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
  • 1980: First manufacturing facility set up at Vatva in Ahmedabad
  • 1983: Entry into the international markets. First Export order to USSR received
  • 1984: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1984: Torrent Laboratories Limited received Udyog Ratna Award.
  • 1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
  • 1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
  • 1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1985: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1987: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1989: Second manufacturing plant commissioned at Indrad
  • 1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
  • 1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1988: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1990: Torrent Exports Limited received National Export Award.
  • 1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
  • 1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1995: Torrent Gujarat Biotech Limited plant commissioned.
  • 1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
  • 1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
  • 1998: State-of-the-art R&D Centre commissioned.
  • 1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
  • 1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
  • 1999: First New Chemical Entity Patented by Torrent Research Center
  • 1999: GCCI Export Appreciation Award
  • 1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
  • 2000: Indrad Plant received ISO 9001:2000 Certificate
  • 2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
  • 2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
  • 2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
  • 2001: Torrent do Brasil Ltda. set up in Brazil
  • 2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
  • 2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
  • 2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
  • 2002: Board for Testing and Calibration Laboratories (NABL).
  • 2002: Addition of a new marketing division, MIND
  • 2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
  • 2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
  • 2003: Torrent Pharma Inc. set up in USA.
  • 2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
  • 2003: Torrent Pharma Philippines Inc. set up.
  • 2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
  • 2004: Restructuring of marketing divisions and addition of new division, Delta.
  • 2004: Torrent Australasia Pty Ltd. incorporated in Australia
  • 2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
  • 2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
  • 2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
  • 2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
  • 2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
  • 2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
  • 2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
  • 2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
  • 2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
  • 2007: Construction of Sikkim Plant started
  • 2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
  • 2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
  • 2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
  • 2009: Baddi Plant awarded Five Star rating by British Safety Council
  • 2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
  • 2010: An advanced facility for Stability Studies set up at Indrad Plant
  • 2010: Entered into the therapeutic area of Gynaecology
  • 2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
  • 2010: Started construction of Dahej manufacturing facility
  • 2010: Commissioned a subsidiary in United Kingdom and Romania
  • 2010: Torrent Research Center develops Long Acting Injectables technology
  • 2010: Foray into oncology segment
  • 2011: Sikkim Plant commences operation
  • 2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
  • 2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
  • 2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2012: Topical Foams system developed by Torrent Research Center
  • 2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
  • 2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
  • 2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
  • 2014: Torrent Pharma's Dahej Plant commences operations
  • 2015: Torrent acquires 100% stake of Zyg Pharma
  • 2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2016: Dahej Plant receives USFDA approval
  • 2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
  • 2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
  • 2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
  • 2017: Acquired Women Healthcare brands from Novartis
  • 2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
  • 2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.18%
1 Week
+3.70%
1 Month
+6.69%
3 Month
+22.61%
6 Month
+16.85%
1 Year
+32.42%
2 Year
+83.97%
5 Year
+110.55%

Ratios View Details

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 33.25 39.94 34.19 57.92 23.80 15.12 9.34 21.47 23.49
Return on Capital Employed (%) 31.66 35.06 26.98 45.63 20.36 13.81 9.75 15.28 17.63
Return on Assets (%) 12.79 15.16 11.71 20.89 10.28 5.81 3.15 7.50 9.20

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 1,422 1,902 2,491 3,494 4,350 4,622 4,724 4,823 5,837
Non Curr. Liab. 620 927 2,505 1,995 2,303 4,142 3,861 3,299 2,924
Curr. Liab. 1,711 2,175 2,824 3,285 2,738 5,202 5,165 5,454 4,892
Minority Int. 0 0 0 0 0 1
Equity & Liab. 3,753 5,004 7,820 8,775 9,392 13,967 13,751 13,577 13,653
Non Curr. Assets 1,192 1,600 3,768 4,086 4,513 8,705 8,714 8,596 8,130
Curr. Assets 2,561 3,404 4,051 4,689 4,879 5,262 5,038 4,981 5,523
Misc. Exp. not W/O
Total Assets 3,753 5,004 7,820 8,775 9,392 13,967 13,751 13,577 13,653

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 3,211 4,185 4,653 6,667 5,816 5,950 7,673 7,939 8,005
Other Income 43 38 286 229 223 299 64 121 76
Total Income 3,255 4,223 4,939 6,896 6,039 6,249 7,736 8,061 8,081
Total Expenditure -2,519 -3,233 -3,633 -3,937 -4,438 -4,601 -5,696 -5,769 -5,538
PBIDT 736 990 1,306 2,959 1,601 1,648 2,040 2,292 2,542
Interest -34 -59 -175 -184 -206 -308 -504 -451 -358
Depreciation -83 -87 -191 -238 -307 -409 -618 -654 -658
Taxation -147 -180 -189 -610 -155 -253 -125 -162 -274
Exceptional Items -37 -194 -357
PAT 435 664 751 1,733 934 678 436 1,025 1,252

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 153 599 810 2,742 1,009 894 1,798 1,393 2,011
Cash Fr. Inv. -242 -356 -2,162 -838 -787 -4,707 -241 199 -449
Cash Fr. Finan. 20 86 1,212 -1,435 -193 3,417 -1,314 -1,549 -1,656
Net Change -68 330 -140 469 29 -395 242 42 -95
Cash & Cash Eqvt 687 955 865 1,050 1,068 702 940 662 573

Shareholding Pattern View Details

9 Qtrs 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%)
Promoter 71.25 71.25 71.25 71.25 71.25 71.25 71.25 71.25 71.25
Public 28.75 28.75 28.75 28.75 28.75 28.75 28.75 28.75 28.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 36.49 36.49 36.49 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 13 Jul 2021
Loss of Share Certificates
Torrent Pharmaceuticals Limited has informed the Exchange about Loss of Share Certificates
Mon, 12 Jul 2021
Loss of Share Certificates
Torrent Pharmaceuticals Limited has informed the Exchange about Loss of Share Certificates
Tue, 06 Jul 2021
Copy of Newspaper Publication
Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Close Crossing Current Week High Close Crossing Current Week High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 703.40 +1.4%
Divi's Laboratories Ltd. 128,088.59 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,411.25 -0.2%
Cipla Ltd. 76,510.04 950.55 +0.3%
Cadila Healthcare Ltd. 62,965.29 605.55 -1.6%
Aurobindo Pharma Ltd. 56,484.48 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. 56,291.69 4,100.95 +4.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.81 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 4,100.95 +4.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.17 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 4,100.95 +4.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%